Product Catalog [{"id":"399","name":"Padcev","price":1070.51,"sku":"Padcev (enfortumab vedotin-ejfv)","brand":"Astellas Pharma Inc.","position":1,"category":"Medicines\/Oncology\/Urothelial carcinoma"},{"id":"350","name":"Trodelvy","price":1971,"sku":"Trodelvy (sacituzumab govitecan-hziy)","brand":"Immunomedics Inc.","position":2,"category":"Medicines\/Oncology\/Urothelial carcinoma"},{"id":"51","name":"Bavencio","price":1296,"sku":"Bavencio (avelumab)","brand":"Merck Serono Europe Limited","position":3,"category":"Medicines\/Oncology\/Urothelial carcinoma"},{"id":"37","name":"Imfinzi","price":1052.33,"sku":"Imfinzi (durvalumab)","brand":"AstraZeneca Pharmaceuticals LP","position":4,"category":"Medicines\/Oncology\/Urothelial carcinoma"},{"id":"35","name":"Keytruda","price":4225.5,"sku":"Keytruda (pembrolizumab)","brand":"Merck Sharp ","position":5,"category":"Medicines\/Oncology\/Urothelial carcinoma"},{"id":"21","name":"Opdivo","price":867.24,"sku":"Opdivo (nivolumab)","brand":"Bristol-Myers Squibb Pharma EEIG","position":6,"category":"Medicines\/Oncology\/Urothelial carcinoma"},{"id":"12","name":"Tecentriq","price":7452.9,"sku":"Tecentriq (atezolizumab)","brand":"Roche Registration Limited","position":7,"category":"Medicines\/Oncology\/Urothelial carcinoma"}]

Urothelial carcinoma access options

Urothelial cancers are a multifocal process, encompassing carcinomas of the bladder, ureters, and renal pelvis at a ratio of 50:3:11. Urothelial carcinoma, also known as transitional cell carcinoma (TCC), is by far the most common type of bladder cancer, starting in the urothelial cells that line the inside of the bladder. Urothelial cells also line other parts of the urinary tract, such as the part of the kidney that connects to the ureter, the ureters, and the urethra. Patients with bladder cancer sometimes have other tumours in these places and so the entire urinary tract needs to be checked. Patients with cancer of the upper urinary tract have a chance of developing bladder cancer... Read more » The global incidence of bladder cancer was 430,000 in 2012. Patients with cancer of the upper urinary tract have a 30% to 50% chance of developing cancer of the bladder at some point in their lives, whilst patients with bladder cancer have a 2% to 3% chance of developing cancer of the upper urinary tract.
  1. Tecentriq
    Tecentriq (Atezolizumab)
    Urothelial Carcinoma, Breast Cancer, Lung Cancer
  2. Opdivo
    Opdivo (Nivolumab)
    Urothelial Carcinoma, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Lymphoma, Skin Cancer
  3. Keytruda
    Keytruda (pembrolizumab)
    Urothelial Carcinoma, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Skin Cancer
  4. Bavencio
    Bavencio (avelumab)
    Urothelial Carcinoma, Kidney Cancer, Skin Cancer
  5. Trodelvy
    Trodelvy (sacituzumab govitecan-hziy)
    Urothelial Carcinoma, Breast Cancer
  6. Imfinzi
    Imfinzi (durvalumab)
    Urothelial Carcinoma, Lung Cancer
  7. Padcev
    Padcev (enfortumab vedotin-ejfv)
    Urothelial Carcinoma
View as Grid List

7 Items

Set Descending Direction
Read more about the latest treatments in Urothelial carcinoma
US 0